Nuclear factor of activated T cells - A transcription factor family as critical regulator in lung and colon cancer

International Journal of Cancer

Volumn 134, Issue 8, 2014, Pages 1767-1775

  Daniel, Carolin ^a   Gerlach, Katharina ^b   Väth, Martin ^c   Neurath, Markus F ^b   Weigmann, Benno ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

cancer; nuclear factor of activated T cells; transcription factor

Indexed keywords

CANCER; NUCLEAR FACTOR OF ACTIVATED T CELLS; TRANSCRIPTION FACTOR;

CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; ENZYME ACTIVATION; HUMANS; INFLAMMATION; LUNG NEOPLASMS; NFATC TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84893774056     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28329     Document Type: Review

References (118)

1. Shaw JP, Utz PJ, Durand DB, et al. Identification of a putative regulator of early T-cell activation genes. Science 1988; 241: 202-5.
2. Flanagan WM, Corthesy B, Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 803-7. (Pubitemid 21912434)
3. Jain J, McCaffrey PG, Miner Z, et al. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993; 365: 352-5. (Pubitemid 23288978)
4. McCaffrey PG, Luo C, Kerppola TK, et al. Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science 1993; 262: 750-4. (Pubitemid 23350696)
5. Jain J, Miner Z, Rao A,. Analysis of the preexisting and nuclear forms of nuclear factor of activated T cells. J Immunol 1993; 151: 837-48. (Pubitemid 23215749)
6. Gerlach K, Daniel C, Lehr HA, et al. Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6-dependent colitis. Cancer Res 2012; 72: 4340-50.
7. Hogan PG, Chen L, Nardone J, et al. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003; 17: 2205-32. (Pubitemid 37128637)
8. Rao A, Luo C, Hogan PG,. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997; 15: 707-47. (Pubitemid 27169297)
9. Serfling E, Berberich-Siebelt F, Chuvpilo S, et al. The role of NF-AT transcription factors in T cell activation and differentiation. Biochim Biophys Acta 2000; 1498: 1-18.
10. Crabtree GR, Olson EN,. NFAT signaling: choreographing the social lives of cells. Cell 2002; 109 (suppl): S67-79. (Pubitemid 34457853)
11. Terui Y, Saad N, Jia S, et al. Dual role of sumoylation in the nuclear localization and transcriptional activation of NFAT1. J Biol Chem 2004; 279: 28257-65. (Pubitemid 38900103)
12. Nayak A, Glockner-Pagel J, Vaeth M, et al. Sumoylation of the transcription factor NFATc1 leads to its subnuclear relocalization and interleukin-2 repression by histone deacetylase. J Biol Chem 2009; 284: 10935-46.
13. Okamura H, Garcia-Rodriguez C, Martinson H, et al. A conserved docking motif for CK1 binding controls the nuclear localization of NFAT1. Mol Cell Biol 2004; 24: 4184-95. (Pubitemid 41070992)
14. Hogan PG, Lewis RS, Rao A,. Molecular basis of calcium signaling in lymphocytes: STIM and ORAI. Annu Rev Immunol 2010; 28: 491-533.
15. Feske S,. Calcium signalling in lymphocyte activation and disease. Nat Rev Immunol 2007; 7: 690-702. (Pubitemid 47327393)
16. 2+-calcineurin-NFAT signaling. Cell 2009; 138: 210,e1.
17. Wu Y, Borde M, Heissmeyer V, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006; 126: 375-87. (Pubitemid 44092960)
18. Aramburu J, Yaffe MB, Lopez-Rodriguez C, et al. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science 1999; 285: 2129-33. (Pubitemid 29451431)
19. Arron JR, Winslow MM, Polleri A, et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006; 441: 595-600. (Pubitemid 43927286)
20. Gwack Y, Sharma S, Nardone J, et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 2006; 441: 646-50. (Pubitemid 43927297)
21. Huang GN, Huso DL, Bouyain S, et al. NFAT binding and regulation of T cell activation by the cytoplasmic scaffolding Homer proteins. Science 2008; 319: 476-81. (Pubitemid 351160583)
22. Patra AK, Avots A, Zahedi RP, et al. An alternative NFAT-activation pathway mediated by IL-7 is critical for early thymocyte development. Nat Immunol 2013; 14: 127-35.
23. Willingham AT, Orth AP, Batalov S, et al. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT. Science 2005; 309: 1570-3. (Pubitemid 41266484)
24. Yoeli-Lerner M, Yiu GK, Rabinovitz I, et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell 2005; 20: 539-50. (Pubitemid 41668639)
25. Wu W, Misra RS, Russell JQ, et al. Proteolytic regulation of nuclear factor of activated T (NFAT) c2 cells and NFAT activity by caspase-3. J Biol Chem 2006; 281: 10682-90. (Pubitemid 43855489)
26. Olabisi OA, Soto-Nieves N, Nieves E, et al. Regulation of transcription factor NFAT by ADP-ribosylation. Mol Cell Biol 2008; 28: 2860-71. (Pubitemid 351556520)
27. Valdor R, Schreiber V, Saenz L, et al. Regulation of NFAT by poly(ADP-ribose) polymerase activity in T cells. Mol Immunol 2008; 45: 1863-71.
28. Daniel C, von Boehmer H,. Extra-thymically induced regulatory T cells: do they have potential in disease prevention? Semin Immunol 2011; 23: 410-7.
29. von Boehmer H, Daniel C,. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat Rev Drug Discov 2013; 12: 51-63.
30. Daniel C, Ploegh H, von Boehmer H,. Antigen-specific induction of regulatory T cells in vivo and in vitro. Methods Mol Biol 2011; 707: 173-85.
31. Daniel C, Nolting J, von Boehmer H,. Mechanisms of self-nonself discrimination and possible clinical relevance. Immunotherapy 2009; 1: 631-44.
32. Kretschmer K, Apostolou I, Verginis P, et al. Regulatory T cells and antigen-specific tolerance. Chem Immunol Allergy 2008; 94: 8-15.
33. Serfling E, Klein-Hessling S, Palmetshofer A, et al. NFAT transcription factors in control of peripheral T cell tolerance. Eur J Immunol 2006; 36: 2837-43. (Pubitemid 44782556)
34. Macian F,. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005; 5: 472-84.
35. Rincon M, Flavell RA,. Transcription mediated by NFAT is highly inducible in effector CD4+ T helper 2 (Th2) cells but not in Th1 cells. Mol Cell Biol 1997; 17: 1522-34. (Pubitemid 27097382)
36. Torgerson TR, Colosia AD, Donahue JP, et al. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol 1998; 161: 6084-92. (Pubitemid 28535979)
37. Kaminski BA, Kadereit S, Miller RE, et al. Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation. Blood 2003; 102: 4608-17. (Pubitemid 37494131)
38. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448: 480-3. (Pubitemid 47123514)
39. Ranger AM, Oukka M, Rengarajan J, et al. Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. Immunity 1998; 9: 627-35. (Pubitemid 28557591)
40. Monticelli S, Rao A,. NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription. Eur J Immunol 2002; 32: 2971-8. (Pubitemid 35238190)
41. Porter CM, Clipstone NA,. Sustained NFAT signaling promotes a Th1-like pattern of gene expression in primary murine CD4+ T cells. J Immunol 2002; 168: 4936-45. (Pubitemid 34495955)
42. Avni O, Lee D, Macian F, et al. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nat Immunol 2002; 3: 643-51. (Pubitemid 34752473)
43. Sun Z, Unutmaz D, Zou YR, et al. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 2000; 288: 2369-73. (Pubitemid 30448162)
44. Shen F, Hu Z, Goswami J, et al. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem 2006; 281: 24138-48. (Pubitemid 44274188)
45. Weigmann B, Lehr HA, Yancopoulos G, et al. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med 2008; 205: 2099-110.
46. Stolfi C, Pallone F, Macdonald TT, et al. Interleukin-21 in cancer immunotherapy: friend or foe? Oncoimmunology 2012; 1: 351-4.
47. Fina D, Sarra M, Fantini MC, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008; 134: 1038-48.
48. Mehta DS, Wurster AL, Weinmann AS, et al. NFATc2 and T-bet contribute to T-helper-cell-subset-specific regulation of IL-21 expression. Proc Natl Acad Sci USA 2005; 102: 2016-21. (Pubitemid 40262004)
49. Kim HP, Korn LL, Gamero AM, et al. Calcium-dependent activation of interleukin-21 gene expression in T cells. J Biol Chem 2005; 280: 25291-7. (Pubitemid 40934624)
50. Baine I, Abe BT, Macian F,. Regulation of T-cell tolerance by calcium/NFAT signaling. Immunol Rev 2009; 231: 225-40.
51. Zheng Y, Josefowicz S, Chaudhry A, et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010; 463: 808-12.
52. Vaeth M, Schliesser U, Muller G, et al. Dependence on nuclear factor of activated T-cells (NFAT) levels discriminates conventional T cells from Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2012; 109: 16258-63.
53. Long M, Park SG, Strickland I, et al. Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 2009; 31: 921-31.
54. Ruan Q, Kameswaran V, Tone Y, et al. Development of Foxp3(+) regulatory t cells is driven by the c-Rel enhanceosome. Immunity 2009; 31: 932-40.
55. Vang KB, Yang J, Pagan AJ, et al. Cutting edge: CD28 and c-Rel-dependent pathways initiate regulatory T cell development. J Immunol 2010; 184: 4074-7.
56. Visekruna A, Huber M, Hellhund A, et al. c-Rel is crucial for the induction of Foxp3(+) regulatory CD4(+) T cells but not T(H)17 cells. Eur J Immunol 2010; 40: 671-6.
57. Sakaguchi S, Sakaguchi N,. Thymus and autoimmunity. Transplantation of the thymus from cyclosporin A-treated mice causes organ-specific autoimmune disease in athymic nude mice. J Exp Med 1988; 167: 1479-85.
58. Oh-Hora M, Yamashita M, Hogan PG, et al. Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. Nat Immunol 2008; 9: 432-43. (Pubitemid 351405113)
59. Koonpaew S, Shen S, Flowers L, et al. LAT-mediated signaling in CD4+CD25+ regulatory T cell development. J Exp Med 2006; 203: 119-29. (Pubitemid 43139651)
60. 2+- dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation. J Biol Chem 2011; 286: 7522-34.
61. Frischbutter S, Gabriel C, Bendfeldt H, et al. Dephosphorylation of Bcl-10 by calcineurin is essential for canonical NF-kappaB activation in Th cells. Eur J Immunol 2011; 41: 2349-57.
62. Bopp T, Palmetshofer A, Serfling E, et al. NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4+ T lymphocytes by CD4+ CD25+ regulatory T cells. J Exp Med 2005; 201: 181-7. (Pubitemid 40189426)
63. Hu H, Djuretic I, Sundrud MS, et al. Transcriptional partners in regulatory T cells: Foxp3, Runx and NFAT. Trends Immunol 2007; 28: 329-32. (Pubitemid 47077927)
64. Sumpter TL, Payne KK, Wilkes DS,. Regulation of the NFAT pathway discriminates CD4+CD25+ regulatory T cells from CD4+CD25- helper T cells. J Leukoc Biol 2008; 83: 708-17. (Pubitemid 351966881)
65. Bandukwala HS, Wu Y, Feuerer M, et al. Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells. Immunity 2011; 34: 479-91.
66. Ponticelli C, Tarantino A, Campise M, et al. From cyclosporine to the future. Transplant Proc 2004; 36: 557S-60S. (Pubitemid 38373928)
67. Bodor J, Fehervari Z, Diamond B, et al. ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur J Immunol 2007; 37: 884-95. (Pubitemid 46925326)
68. Neal JW, Clipstone NA,. A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. J Biol Chem 2003; 278: 17246-54. (Pubitemid 36799606)
69. Wang JH, Wang NN, Xie JL, et al. Restricted epithelial proliferation by lacritin via PKC alpha-dependent NFAT and mTOR pathways. J Cell Biol 2006; 174: 689-700.
70. Suehiro J, Hamakubo T, Kodama T, et al. Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3. Blood 2010; 115: 2520-32.
71. Schweighofer B, Testori J, Sturtzel C, et al. The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thromb Haemost 2009; 102: 544-54.
72. Jang GH, Park IS, Yang JH, et al. Differential functions of genes regulated by VEGF-NFATc1 signaling pathway in the migration of pulmonary valve endothelial cells. FEBS Lett 2010; 584: 141-6.
73. Acevedo LM, Cheresh DA,. Suppressing NFAT increases VEGF signaling in hemangiomas. Cancer Cell 2008; 14: 429-30.
74. Zaichuk TA, Shroff EH, Emmanuel R, et al. Nuclear factor of activated T cells balances angiogenesis activation and inhibition. J Exp Med 2004; 199: 1513-22. (Pubitemid 38780406)
75. Baksh S, Widlund HR, Frazer-Abel AA, et al. NFATc2-mediated repression of cyclin-dependent kinase 4 expression. Mol Cell 2002; 10: 1071-81. (Pubitemid 35453825)
76. Carvalho LD, Teixeira LK, Carrossini N, et al. The NFAT1 transcription factor is a repressor of cyclin A2 gene expression. Cell Cycle 2007; 6: 1789-95. (Pubitemid 47327933)
77. Chuvpilo S, Jankevics E, Tyrsin D, et al. Autoregulation of NFATc1/A expression facilitates effector T cells to escape from rapid apoptosis. Immunity 2002; 16: 881-95. (Pubitemid 34786486)
78. Serfling E, Avots A, Klein-Hessling S, et al. NFATc1/alphaA: the other face of NFAT factors in lymphocytes. Cell Commun Signal 2012; 10: 16.
79. Bhattacharyya S, Deb J, Patra AK, et al. NFATc1 affects mouse splenic B cell function by controlling the calcineurin-NFAT signaling network. J Exp Med 2011; 208: 823-39.
80. Faget DV, Lucena PI, Robbs BK, et al. NFAT1 C-terminal domains are necessary but not sufficient for inducing cell death. PLoS One 2012; 7: e47868.
81. Robbs BK, Cruz ALS, Werneck MBF, et al. Dual roles for NFAT transcription factor genes as oncogenes and tumor suppressors. Mol Cell Biol 2008; 28: 7168-81.
82. Buchholz M, Schatz A, Wagner M, et al Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. Embo J 2006; 25: 3714-24. (Pubitemid 44264881)
83. Koenig A, Linhart T, Schlengemann K, et al. NFAT-Induced histone acetylation relay switch promotes c-Myc-dependent growth in pancreatic cancer cells. Gastroenterology 2010; 138: 1189-99,U487.
84. Baumgart S, Glesel E, Singh G, et al. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Gastroenterology 2012; 142: 388-98 e1-7.
85. 2+/NFAT-dependent pathways. Oncogene 2007; 26: 7380-5. (Pubitemid 350115979)
86. Flockhart RJ, Armstrong JL, Reynolds NJ, et al. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Brit J Cancer 2009; 101: 1448-55.
87. Sales KJ, Maldonado-Perez D, Grant V, et al. Prostaglandin F-2 alpha-F-prostanoid receptor regulates CXCL8 expression in endometrial adenocarcinoma cells via the calcium-calcineurin-NFAT pathway. Biochim Biophys Acta 2009; 1793: 1917-28.
88. Sales KJ, Grant V, Cook IH, et al. Interleukin-11 in endometrial adenocarcinoma is regulated by prostaglandin F(2 alpha)-F-prostanoid receptor interaction via the calcium-calcineurin-nuclear factor of activated T cells pathway and negatively regulated by the regulator of calcineurin-1. Am J Pathol 2010; 176: 435-45.
89. Pham LV, Tamayo AT, Li C, et al. An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas. Blood 2010; 116: 3899-906.
90. Wang S, Kang X, Cao S, et al. Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma. Dig Dis Sci 2012; 57: 3184-8.
91. Seifert A, Rau S, Kullertz G, et al. TCDD induces cell migration via NFATc1/ATX-signaling in MCF-7 cells. Toxicol Lett 2009; 184: 26-32.
92. Lapouge G, Marcias G, Erdmann E, et al. Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol 2008; 617: 529-34.
93. Yiu GK, Kaunisto A, Chin YR, et al. NFAT promotes carcinoma invasive migration through glypican-6. Biochem J 2011; 440: 157-66.
94. Li GD, Zhang X, Li R, et al. CHP2 activates the calcineurin/nuclear factor of activated T cells signaling pathway and enhances the oncogenic potential of HEK293 cells. J Biol Chem 2008; 283: 32660-8.
95. Siamakpour-Reihani S, Caster J, Bandhu Nepal D, et al. The role of calcineurin/NFAT in SFRP2 induced angiogenesis-a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. PLoS One 2011; 6: e20412.
96. Ding J, Li J, Xue C, et al. Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells. J Biol Chem 2006; 281: 24405-13. (Pubitemid 44274213)
97. Fougere M, Gaudineau B, Barbier J, et al. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene. Oncogene 2010; 29: 2292-301.
98. Maxeiner JH, Karwot R, Sauer K, et al. A key regulatory role of the transcription factor NFATc2 in bronchial adenocarcinoma via CD8+ T lymphocytes. Cancer Res 2009; 69: 3069-76.
99. Werneck MB, Vieira-de-Abreu A, Chammas R, et al. NFAT1 transcription factor is central in the regulation of tissue microenvironment for tumor metastasis. Cancer Immunol Immunother 2011; 60: 537-46.
100. Qin L, Zhao D, Liu X, et al. Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway. Mol Cancer Res 2006; 4: 811-20. (Pubitemid 44877011)
101. Duque J, Fresno M, Iniguez MA,. Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2. J Biol Chem 2005; 280: 8686-93. (Pubitemid 40409556)
102. Burstein E, Fearon ER,. Colitis and cancer: a tale of inflammatory cells and their cytokines. J Clin Invest 2008; 118: 464-7. (Pubitemid 351206535)
103. Hanada T, Kobayashi T, Chinen T, et al. IFN gamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 2006; 203: 1391-7. (Pubitemid 43877600)
104. Rizzo A, Waldner MJ, Stolfi C, et al. Smad7 Expression in T cells prevents colitis-associated cancer. Cancer Res 2011; 71: 7423-32.
105. Stolfi C, Rizzo A, Franze E, et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med 2011; 208: 2279-90.
106. Nilsson LM, Sun ZW, Nilsson J, et al. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 2007; 292: C1167-78. (Pubitemid 46440403)
107. Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91-102.
108. Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009; 15: 103-13.
109. Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257-72.
110. Bromberg J, Wang TC,. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79-80.
111. Waldner MJ, Neurath MF,. Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol 2009; 31: 249-56.
112. Gremese E, Ferraccioli GF,. Benefit/risk of cyclosporine in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22: S101-7. (Pubitemid 39328361)
113. Kaufman DB, Shapiro R, Lucey MR, et al. Immunosuppression: practice and trends. Am J Transplant 2004; 4 (suppl 9): 38-53. (Pubitemid 38858994)
114. Griffiths B, Emery P,. The treatment of lupus with cyclosporin A. Lupus 2001; 10: 165-70. (Pubitemid 32410072)
115. Kiani A, Rao A, Aramburu J,. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000; 12: 359-72.
116. Muller MR, Rao A,. Linking calcineurin activity to leukemogenesis. Nat Med 2007; 13: 669-71. (Pubitemid 46889744)
117. Bechstein WO,. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000; 13: 313-26.
118. Olyaei AJ, de Mattos AM, Bennett WM,. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384-9. (Pubitemid 34020400)